Frequently Asked Questions about Sensei Biotherapeutics, Inc. (SNSE)

Name: Sensei Biotherapeutics, Inc. (SNSE) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Sensei Biotherapeutics, Inc. (SNSE) do?

Accepted Answer

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused...

Question 2

Is Sensei Biotherapeutics, Inc. (SNSE) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of SNSE reveals an Altman Z-Score of -13.95 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if SNSE fits their risk profile.

Question 3

What is the current P/E ratio for SNSE?

Accepted Answer

As of the latest trading session, Sensei Biotherapeutics, Inc. (SNSE) has a trailing P/E ratio of -1.78.

Question 4

Who is the CEO of Sensei Biotherapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Sensei Biotherapeutics, Inc. is Christopher W. Gerry.

Question 5

What was SNSE's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Sensei Biotherapeutics, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does SNSE pay a dividend?

Accepted Answer

Sensei Biotherapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does SNSE have?

Accepted Answer

In its latest reporting period, Sensei Biotherapeutics, Inc. generated $-0.02B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of Sensei Biotherapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Sensei Biotherapeutics, Inc. (SNSE) is currently 2.02.

Question 9

What is the Price-to-Sales (P/S) ratio of SNSE?

Accepted Answer

Based on trailing twelve-month data, Sensei Biotherapeutics, Inc. (SNSE) trades at a Price-to-Sales (P/S) ratio of -8.24.

Question 10

What is Sensei Biotherapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Sensei Biotherapeutics, Inc. (SNSE) has a Return on Equity (ROE) of -83.59%, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	22.9M	4.3M	18.6M	1.5M	-7.2M
2024-12	45.4M	7M	38.4M	3.8M	-6.1M
2023-12	74.4M	9.5M	64.9M	6.2M	-6.8M
2022-12	118.4M	15M	103.4M	8M	-9.8M
2021-12	153.2M	6.7M	146.5M	2.4M	-4.8M